<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335">
  <stage>Registered</stage>
  <submitdate>30/08/2005</submitdate>
  <approvaldate>6/09/2005</approvaldate>
  <actrnumber>ACTRN12605000311651</actrnumber>
  <trial_identification>
    <studytitle>Metformin in gestational diabetes: the offspring follow up</studytitle>
    <scientifictitle>Metformin in gestational diabetes: follow up of offspring of mothers treated with insulin compared with metformin</scientifictitle>
    <utrn />
    <trialacronym>MiG:TOFU</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Gestational Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Offspring of women who have been randomised to metformin or insulin in the MiG study are being followed through childhood to assess growth and development.</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Markers of adiposity in the offspring.</outcome>
      <timepoint>Measured at 2 years of age currently and will be remeasured through childhood.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Markers of insulin sensitivity in the offspring.</outcome>
      <timepoint>Measured at 2 years of age currently and will be remeasured through childhood.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Neurodeveopmental </outcome>
      <timepoint>Assessment at age 2 years and at intervals through childhood.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Offspring of women who were randomsied in the metformin in geststional diabetes study</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/12/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>HRC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Human Research Council</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>When women with gestational diabetes were randomsied to insulin or metformin treatment in the MiG study, they were asked to consent to follow up of the offpsring. We are now doing the first follow up at 2 ears including detailed body composition measurements, physcial examination and neurodevelopmental assessment. We plan to continue longterm follow up to see if metformin exposure in utero modifies later risks of obesity and type 2 diabetes</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Janet Rowan</name>
      <address>National Women's Health
Private bag 92024
Auckland 1003</address>
      <phone>+ 64 9 6389909</phone>
      <fax>+64 9 307 4918</fax>
      <email>jrowan@internet.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Janet Rowan</name>
      <address>National Women's Health
Private Bag 92024
Auckland 1003</address>
      <phone>+64 9 6389909</phone>
      <fax>+ 64 9 3074918</fax>
      <email>jrowan@internet.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>